iSign Solutions (ISGN) 10-Q 16 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 13, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Communication Intelligence Corp
Entity Central Index Key	727,634
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
EntityVoluntaryFilers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		234,307,542

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 358	$ 775
Accounts receivable, net of allowance of $86 at September 30, 2015 and $22 at December 31, 2014	159	122
Prepaid expenses and other current assets	125	80
Total current assets	642	977
Property and equipment, net	17	11
Patents, net	673	933
Other assets	29	29
Total assets	1,361	1,950
Current liabilities:
Short-term debt	250
Accounts payable	420	328
Accrued compensation	272	293
Other accrued liabilities	477	338
Deferred revenue	353	257
Total current liabilities	1,772	1,216
Deferred revenue long-term	490	700
Deferred rent	2	41
Derivative liability		18
Other long-term liabilities	21	28
Total liabilities	$ 2,285	$ 2,003
Commitments and Contingencies
Equity (Deficit)
Common stock	$ 2,407	$ 2,407
Treasury shares	(325)	(325)
Additional paid in capital	93,604	94,995
Accumulated deficit	(126,082)	(123,199)
Accumulated other comprehensive loss	(14)	(14)
Total CIC stockholder's equity	(388)	483
Non-Controlling interest	(536)	(536)
Total deficit	(924)	(53)
Total liabilities and shareholders' equity	1,361	1,950
Series A-1 Preferred Stock [Member]
Equity (Deficit)
Preferred Stock	929	875
Total deficit	929	875
Series B Preferred Stock [Member]
Equity (Deficit)
Preferred Stock	11,320	10,381
Total deficit	11,320	10,381
Series C Preferred Stock [Member]
Equity (Deficit)
Preferred Stock	5,934	5,553
Total deficit	5,934	5,553
Series D-1 Preferred Stock [Member]
Equity (Deficit)
Preferred Stock	6,724	5,139
Total deficit	6,724	5,139
Series D-2 Preferred Stock [Member]
Equity (Deficit)
Preferred Stock	5,115	4,671
Total deficit	$ 5,115	$ 4,671

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Accounts receivable, allowance	$ 86	$ 22

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue:
Product	$ 127	$ 85	$ 510	$ 491
Maintenance	224	200	654	568
Total revenues	351	285	1,164	1,059
Cost of sales:
Product	40	26	185	69
Maintenance	29	20	102	111
Research and development	446	476	1,467	1,549
Sales and marketing expense	216	303	756	942
General and administrative expense	470	410	1,551	1,325
Total operating costs and expenses	1,201	1,235	4,061	3,996
Loss from operations	(850)	(950)	(2,897)	(2,937)
Other income, net		49		51
Interest expense	(3)	(13)	(3)	(258)
(Loss) gain on derivative liability		2	17	5
Net loss	(853)	(912)	(2,883)	(3,139)
Accretion of beneficial conversion feature, preferred stock:
Related party		(103)	(458)	(186)
Other		(68)	(69)	(416)
Preferred stock dividends:
Related party	(408)	(345)	(1,154)	(1,014)
Other	(411)	(363)	(1,181)	(975)
Net loss attributable to common stockholders	$ (1,672)	$ (1,791)	$ (5,745)	$ (5,730)
Basic and diluted loss per common share	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.02)
Weighted average common shares outstanding, basic and diluted	234,308	232,646	234,308	232,588

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net loss	$ (2,883)	$ (3,139)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation and amortization	267	278
Stock-based employee compensation	487	242
Warrants cost issued as interest expense		258
Gain on derivative liability	(17)	(5)
Changes in operating assets and liabilities:
Accounts receivable, net	(37)	195
Prepaid expenses and other assets	(45)	(31)
Accounts payable	92	(106)
Accrued compensation	(21)	(50)
Other accrued and long-term liabilities	93	15
Deferred revenue	(114)	(165)
Net cash used in operating activities	(2,178)	(2,508)
Cash flows from investing activities:
Acquisition of property and equipment	(14)	(4)
Net cash used in investing activities	(14)	(4)
Cash flows from financing activities:
Proceeds from issuance of short-term debt	250
Net cash provided by financing activities	$ 1,775	$ 2,208
Effect of exchange rate changes on cash and cash equivalents
Net decrease in cash and cash equivalents	$ (417)	$ (304)
Cash and cash equivalents at beginning of period	775	945
Cash and cash equivalents at end of period	358	$ 641
Supplemental disclosure of cash flow information:
Interest paid	$ 3
Income tax paid
Non-cash financing and investing transactions:
Dividends on Preferred Stock	$ 2,335	$ 1,989
Accretion of beneficial conversion feature on issuance of convertible Preferred Stock	498	337
Accretion of beneficial conversion feature on issuance of Preferred Stock dividends	29	265
Conversion of Series C Preferred Stock into Common Stock		1
Series D-1 Preferred Stock [Member]
Cash flows from financing activities:
Proceeds from issuance of Series D Preferred Stock, net of issuance costs	1,525	1,828
Non-cash financing and investing transactions:
Dividends on Preferred Stock	516	329
Accretion of beneficial conversion feature on issuance of Preferred Stock dividends	$ 16	151
Series D-2 Preferred Stock [Member]
Cash flows from financing activities:
Proceeds from issuance of Series D Preferred Stock, net of issuance costs		380
Non-cash financing and investing transactions:
Dividends on Preferred Stock	$ 445	$ 400
Accretion of beneficial conversion feature on issuance of Preferred Stock dividends

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Series D-1 Preferred Stock [Member]
Series D Preferred Stock issuance costs	$ 37	$ 84
Series D-2 Preferred Stock [Member]
Series D Preferred Stock issuance costs		$ 17

Nature of business, basis of pr

Nature of business, basis of presentation and summary of significant accounting policies	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of business, basis of presentation and summary of significant accounting policies	1. Nature of business and summary of significant accounting policies Nature of Business Communication Intelligence Corporation and its subsidiary (the "Company" or "CIC") is a leading provider of digital transaction management (DTM) software enabling fully digital (paperless) business processes. The Company's solutions encompass a wide array of functionality and services, including electronic signatures, biometric authentication and simple-to-complex workflow management. These solutions are available across virtually all enterprise, desktop and mobile environments as a seamlessly integrated platform for both ad-hoc and fully automated transactions. The Company's software can be deployed both on-premise and as a cloud-based service, with the ability to easily transition between deployment models. To date, the Company primarily has delivered its solutions to channel partners and end-user customers in the financial services industry. The Company's products include SignatureOne® Ceremony™ Server, the iSign® suite of products and services, including iSign® Enterprise and iSign® Console™, and Sign-it® programs. Basis of Presentation The financial information contained herein should be read in conjunction with the Company's consolidated audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2014. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America ("GAAP") for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company's results of operations and cash flows for the periods presented. The Company's interim results are not necessarily indicative of the results to be expected for the entire year. Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant cumulative losses since its inception and, at September 30, 2015, the Company's accumulated deficit was $126,082. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of September 30, 2015, the Company's cash balance was $358. These factors raise substantial doubt about the Company's ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company's business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accounting Changes and Recent Accounting Pronouncements Accounting Standards Issued But Not Yet Adopted Accounting standards that have been issued or proposed by the FASB or other standards-setting bodies are not expected to have a material impact on the Company's financial position, results of operations and cash flows.

Concentrations

Concentrations	9 Months Ended
	Sep. 30, 2015
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	2. Concentrations The following table summarizes accounts receivable and revenue concentrations: Accounts Receivable Total Revenue Total Revenue 2015 2014 2015 2014 2015 2014 Customer #1 38% 46% - 17% 12% 11% Customer #2 24% - 17% - - - Customer #3 - - 10% 12% - 10% Customer #4 - 12% - - - - Customer #5 - 19% - - - - Customer #6 - - - 10% 16% - Customer #7 - - - - 17% 14% Total concentration 62% 77% 27% 39% 45% 35%

Patents

Patents	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	3. Patents The Company performs an intangible asset impairment analysis at least annually or whenever circumstances or events indicate such assets might be impaired. The Company would recognize an impairment charge in the event the net book value of such assets exceeded the future undiscounted cash flows attributable to such assets. Management completed an analysis of the Company's patents as of December 31, 2014. Based on that analysis, the Company concluded that no impairment of the carrying value of the patents existed. The Company believes that no events or circumstances changed during the three and nine months ended September 30, 2015 that would impact this conclusion. Amortization of patent costs was $87 and $260 for the three and nine-month periods ended September 30, 2015 and $90 and $270 for the three- and nine-month periods ended September 30, 2014. The following table summarizes the amortizable intangible assets: Amortizable intangible assets: September 30, 2015 December 31, 2014 Carrying Accumulated Net Value Carrying Accumulative Net Value Patents $ 6,745 $ (6,072) $ 673 $ 6,745 $ (5,812) $ 933

Short-term note payable

Short-term note payable	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Short-term notes payable	4. Short-term note payable On September 29, 2015, the Company issued a demand note for an aggregate amount of $250 to an affiliate of the Company. This note bears interest at the rate of 10% per annum and both the principal and interest accrued are payable on demand.

Net loss per share

Net loss per share	9 Months Ended
	Sep. 30, 2015
Net loss per share [Abstract]
Net loss per share	5. Net loss per share The Company calculates basic net loss per share based on the weighted average number of shares outstanding, and when applicable, diluted income per share, which is based on the weighted average number of shares and potential dilutive shares outstanding. The following table lists shares and warrants that were excluded from the calculation of dilutive earnings per share as the exercise of such options and warrants and the conversion of such preferred shares would be anti-dilutive: For the Nine Months Ended September 30, 2015 September 30, 2014 Stock options 106,495 70,960 Warrants 237,822 173,814 Preferred shares as if converted Series A-1 Preferred Stock 6,633 7,818 Series B Preferred Stock 304,430 275,888 Series C Preferred Stock 238,056 215,668 Series D-1 Preferred Stock 350,127 251,435 Series D-2 Preferred Stock 124,470 112,737

Equity

Equity	9 Months Ended
	Sep. 30, 2015
Stockholders' Equity [Abstract]
Stockholders' Equity	6. Equity Stock-based compensation expense is based on the estimated grant date fair value of the portion of stock-based payment awards that are ultimately expected to vest during the period. The grant date fair value of stock-based awards to employees and directors is calculated using the Black-Scholes-Merton valuation model. Forfeitures of stock-based payment awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated average forfeiture rate for the three months ended September 30, 2015 and 2014, was approximately 7.89% and 9.75%, respectively, based on historical data. Valuation and Expense Information: The weighted-average fair value of stock-based compensation is based on the Black-Scholes-Merton valuation model. Forfeitures are estimated and it is assumed no dividends will be declared. The estimated fair value of stock-based compensation awards to employees is amortized using the accrual method over the vesting period of the options. The fair value calculations are based on the following assumptions: Nine Months Ended Nine Months Ended Risk free interest rate 0.04% - 3.28% 0.04% - 3.73% Expected life (years) 3.26 - 6.33 2.82 - 7.00 Expected volatility 120.74% - 198.38% 93.63% - 198.38% Expected dividends None None There were no stock options granted during the three month period ended September 30, 2015. The Company granted 36,633 stock options during the nine months ended September 30, 2015 at a weighted average exercise price of $0.0224 per share. There were no stock options exercised during the three- and nine-months ended September 30, 2015. There were no stock options granted during the three months ended September 30, 2014. The Company granted 2,500 stock options during the nine months ended September 30, 2014 at a weighted average exercise price of $0.0273 per share. There were no stock options exercised during the three- and nine-months ended September 30, 2014. The following table summarizes the allocation of stock-based compensation expense related to stock option grants for the three- and nine-month periods ended September 30, 2015 and 2014. Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Research and development $ 35 $ 16 $ 148 $ 64 Sales and marketing $ 26 $ 17 $ 112 $ 54 General and administrative $ 47 $ 29 $ 192 $ 112 Director options $ 8 $ 3 $ 35 $ 12 Stock-based compensation expense $ 116 $ 65 $ 487 $ 242 A summary of option activity under the Company's plans as of September 30, 2015 and 2014 is as follows: Options 2015 2014 Shares Weighted Share Weighted (Years) Aggregate Value Shares Weighted Share Weighted (Years) Aggregate Value Outstanding at January 1, 72,012 $ 0.04 $ - 69,537 $ 0.05 $ - Granted 36,633 $ 0.02 $ - 2,500 $ 0.03 $ - Exercised - - $ - - $ - $ - Forfeited or expired (2,150) $ 0.03 $ - (1,077) $ 0.05 $ - Outstanding at 106,495 $ 0.04 4.39 $ - 70,960 $ 0.05 4.30 $ - Vested and 103,820 $ 0.03 3.21 $ - 63,996 $ 0.05 4.30 $ - Exercisable at September 30 69,757 $ 0.04 3.53 $ - 55,102 $ 0.05 3.98 $ - The following table summarizes significant ranges of outstanding and exercisable options as of September 30, 2015: Range of Exercise Prices Options Outstanding Options Exercisable Number Weighted Weighted Number Weighted $0.01 - $0.02 3,000 6.23 $ 0.02 584 $ 0.02 $0.02 - $0.03 53,170 5.21 $ 0.02 23,107 $ 0.02 $0.03 - $0.06 31,416 4.06 $ 0.05 27,157 $ 0.05 $0.06 - $0.20 18,909 2.32 $ 0.07 18,909 $ 0.07 106,495 4.39 $ 0.04 69,757 $ 0.04 The following table summarizes the Company's non-vested option shares as of September 30, 2015: Non-vested Option Shares Shares Weighted Average Non-vested at January 1, 2015 14,954 $ 0.04 Granted 36,633 $ 0.02 Forfeited (1,020) $ 0.02 Vested (13,829) $ 0.03 Non-vested at September 30, 2015 36,738 $ 0.02 As of September 30, 2015, there was $363 of total unrecognized compensation expense related to non-vested stock-based compensation arrangements granted under the plans. The unrecognized compensation expense is expected to be realized over a weighted average period of 3.2 years. Preferred Stock Information with respect to the class of Preferred Stock at September 30, 2015 is as follows: Class of Annual Annual Liquidation Conversion Total Common Series A-1 8% Quarterly in $ 1.00 $ 0.1400 929 6,633 Series B 10% Quarterly in $ 1.50 $ 0.0433 13,191 304,430 Series C 10% Quarterly in $ 1.50 $ 0.0225 5,356 238,056 Series D-1 10% Quarterly in $ 1.00 $ 0.0225 7,878 350,127 Series D-2 10% Quarterly in $ 1.00 $ 0.0500 6,223 124,470 Information with respect to in-kind dividends issued on the Company's Preferred Stock for the three and nine-month periods ended September 30, 2015 and September 30, 2014 is as follows: Dividends Beneficial Conversion Feature Related to Dividends Three Months Ended Nine Months Ended Three Months Ended Nine Months Ended 2015 2014 2015 2014 2015 2014 2015 2014 Series A-1 $ 18 $ 22 $ 53 $ 63 $ - $ - $ - $ - Series B 324 294 939 852 - - - - Series C 132 119 382 345 - 64 13 114 Series D-1 192 128 516 329 - 107 16 151 Series D-2 153 145 445 400 - - - - Total $ 819 $ 708 $ 2,335 $ 1,989 $ - $ 171 $ 29 $ 265 Series D Preferred Stock On February 7, 2014, the Company sold for $733 in cash, net of a $47 administrative fee paid in cash to SG Phoenix and a nonrelated third party, 520 shares of Series D-1 Preferred Stock and 260 shares of Series D-2 Preferred Stock. The investors received one hundred percent (100%) warrant coverage. These warrants have an exercise price of $0.0225 per share, are immediately exercisable and expire December 31, 2016. The warrants are exercisable in whole or in part and contain a cashless exercise provision. On March 6, 2014, the Company sold for $406 in cash, net of $4 in administrative fees paid in cash to an unrelated third party, 273 shares of Series D-1 Preferred Stock and 137 shares of Series D-2 Preferred Stock. The investors received one hundred percent (100%) warrant coverage. These warrants have an exercise price of $0.0275 per share, are immediately exercisable and expire December 31, 2016. The warrants are exercisable in whole or in part and contain a cashless exercise provision. SG Phoenix received warrants to purchase 3,000 shares of common stock, and two unrelated parties received warrants to purchase an aggregate of 1,600 shares of common stock in payment of administrative and related fees associated with the financings, in addition to the cash payments discussed above. These warrants have an exercise price of $0.0275 per share, are immediately exercisable and expire three (3) years from the date of issuance. The warrants are exercisable in whole or in part and contain a cashless exercise provision. On March 24, 2015, the Company sold for $1,200 in cash, net of $33 in administrative fees paid in cash to SG Phoenix, 1,233 shares of Series D-1 Preferred Stock. The investors received 27,400 warrants, immediately exercisable into common stock of the Company at an exercise price of $0.0225 per share. The warrants expire March 23, 2018. The Company ascribed a value of $366 to the warrants using the Black-Scholes-Merton pricing model. See the warrant table below for more detail. The warrants are exercisable in whole or in part and contain a cashless exercise provision. On July 23, 2015, the Company sold for $325 in cash, net of $4 in administrative fees paid in cash to SG Phoenix, 329 Shares of Series D-1 Preferred Stock. The investors received 13,160 warrants, immediately exercisable into common stock of the Company at $0.0125 per share. The warrants expire July 22, 2018. The Company ascribed a value of $91 to the warrants using the Black-Scholes-Merton pricing model. See the warrant table below for more detail. The warrants are exercisable in whole or in part and contain a cashless exercise provision. Warrants On February 23, 2015, the Company and Venture Champion Asia Limited, an affiliate of IGC Global Limited, mutually agreed to terminate the $2,000 Credit Agreement signed in May 2014. At the time of the termination of the Credit Agreement, no amount was owed by the Company under the Credit Agreement, and contemporaneously with the termination of the Credit Agreement, the 10,909 warrants were likewise terminated. A summary of the warrant activity is as follows: September 30, 2015 September 30, 2014 Warrants Weighted Warrants Weighted Outstanding at beginning of period 213,521 $ 0.0289 77,155 $ 0.0289 Issued 40,560 0.0193 124,711 0.0275 Expired/Cancelled (16,259) 0.0500 (28,052) 0.0225 Outstanding at end of period 237,822 $ 0.0264 173,814 $ 0.0286 Exercisable at end of period 237,822 $ 0.0264 173,814 $ 0.0286 A summary of the status of the warrants outstanding and exercisable as of September 30, 2015 is as follows: Number of Warrants Weighted Average Remaining Life Weighted Average Exercise Price Warrants 27,400 2.52 $ 0.0225 Warrants 193,968 1.26 $ 0.0275 Warrants 3,294 0.13 $ 0.0500 Warrants 13,160 2.83 $ 0.0125 237,822 1.48 $ 0.0264

Nature of business, basis of 13

Nature of business, basis of presentation and summary of significant accounting policies (Policies)	9 Months Ended
	Sep. 30, 2015
Summary of Significant Accounting Policies
Basis of presentation	Basis of Presentation The financial information contained herein should be read in conjunction with the Company's consolidated audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2014. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America ("GAAP") for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company's results of operations and cash flows for the periods presented. The Company's interim results are not necessarily indicative of the results to be expected for the entire year.
Going concern and management plans	Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant cumulative losses since its inception and, at September 30, 2015, the Company's accumulated deficit was $126,082. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of September 30, 2015, the Company's cash balance was $358. These factors raise substantial doubt about the Company's ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company's business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Recently issued accounting pronouncement	Accounting Changes and Recent Accounting Pronouncements Accounting Standards Issued But Not Yet Adopted Accounting standards that have been issued or proposed by the FASB or other standards-setting bodies are not expected to have a material impact on the Company's financial position, results of operations and cash flows.
Patents	The Company performs an intangible asset impairment analysis at least annually or whenever circumstances or events indicate such assets might be impaired. The Company would recognize an impairment charge in the event the net book value of such assets exceeded the future undiscounted cash flows attributable to such assets.
Net loss per share	The Company calculates basic net loss per share based on the weighted average number of shares outstanding, and when applicable, diluted income per share, which is based on the weighted average number of shares and potential dilutive shares outstanding.
Share-based payment	Stock-based compensation expense is based on the estimated grant date fair value of the portion of stock-based payment awards that are ultimately expected to vest during the period. The grant date fair value of stock-based awards to employees and directors is calculated using the Black-Scholes-Merton valuation model. Forfeitures of stock-based payment awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

Concentration (Tables)

Concentration (Tables)	9 Months Ended
	Sep. 30, 2015
Risks and Uncertainties [Abstract]
Schedule of accounts receivable and revenue concentration	The following table summarizes accounts receivable and revenue concentrations: Accounts Receivable Total Revenue Total Revenue 2015 2014 2015 2014 2015 2014 Customer #1 38% 46% - 17% 12% 11% Customer #2 24% - 17% - - - Customer #3 - - 10% 12% - 10% Customer #4 - 12% - - - - Customer #5 - 19% - - - - Customer #6 - - - 10% 16% - Customer #7 - - - - 17% 14% Total concentration 62% 77% 27% 39% 45% 35%

Patents (Tables)

Patents (Tables)	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets	The following table summarizes the amortizable intangible assets: Amortizable intangible assets: September 30, 2015 December 31, 2014 Carrying Accumulated Net Value Carrying Accumulative Net Value Patents $ 6,745 $ (6,072) $ 673 $ 6,745 $ (5,812) $ 933

Net loss per share (Tables)

Net loss per share (Tables)	9 Months Ended
	Sep. 30, 2015
Net loss per share [Abstract]
Schedule of Antidilutive Securities Excluded from Calculation of Earnings Per Share	The following table lists shares and warrants that were excluded from the calculation of dilutive earnings per share as the exercise of such options and warrants and the conversion of such preferred shares would be anti-dilutive: For the Nine Months Ended September 30, 2015 September 30, 2014 Stock options 106,495 70,960 Warrants 237,822 173,814 Preferred shares as if converted Series A-1 Preferred Stock 6,633 7,818 Series B Preferred Stock 304,430 275,888 Series C Preferred Stock 238,056 215,668 Series D-1 Preferred Stock 350,127 251,435 Series D-2 Preferred Stock 124,470 112,737

Equity (Tables)

Equity (Tables)	9 Months Ended
	Sep. 30, 2015
Stockholders' Equity [Abstract]
Key assumptions for fair value calculation, stock options	The weighted-average fair value of stock-based compensation is based on the Black-Scholes-Merton valuation model. Forfeitures are estimated and it is assumed no dividends will be declared. The estimated fair value of stock-based compensation awards to employees is amortized using the accrual method over the vesting period of the options. The fair value calculations are based on the following assumptions: Nine Months Ended Nine Months Ended Risk free interest rate 0.04% - 3.28% 0.04% - 3.73% Expected life (years) 3.26 - 6.33 2.82 - 7.00 Expected volatility 120.74% - 198.38% 93.63% - 198.38% Expected dividends None None
Allocation of stock-based compensation expense related to stock option grants	The following table summarizes the allocation of stock-based compensation expense related to stock option grants for the three- and nine-month periods ended September 30, 2015 and 2014. Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Research and development $ 35 $ 16 $ 148 $ 64 Sales and marketing $ 26 $ 17 $ 112 $ 54 General and administrative $ 47 $ 29 $ 192 $ 112 Director options $ 8 $ 3 $ 35 $ 12 Stock-based compensation expense $ 116 $ 65 $ 487 $ 242
Summary of option activity	A summary of option activity under the Company's plans as of September 30, 2015 and 2014 is as follows: Options 2015 2014 Shares Weighted Share Weighted (Years) Aggregate Value Shares Weighted Share Weighted (Years) Aggregate Value Outstanding at January 1, 72,012 $ 0.04 $ - 69,537 $ 0.05 $ - Granted 36,633 $ 0.02 $ - 2,500 $ 0.03 $ - Exercised - - $ - - $ - $ - Forfeited or expired (2,150) $ 0.03 $ - (1,077) $ 0.05 $ - Outstanding at 106,495 $ 0.04 4.39 $ - 70,960 $ 0.05 4.30 $ - Vested and 103,820 $ 0.03 3.21 $ - 63,996 $ 0.05 4.30 $ - Exercisable at September 30 69,757 $ 0.04 3.53 $ - 55,102 $ 0.05 3.98 $ -
Summary of the significant ranges of outstanding and exercisable options	The following table summarizes significant ranges of outstanding and exercisable options as of September 30, 2015: Range of Exercise Prices Options Outstanding Options Exercisable Number Weighted Weighted Number Weighted $0.01 - $0.02 3,000 6.23 $ 0.02 584 $ 0.02 $0.02 - $0.03 53,170 5.21 $ 0.02 23,107 $ 0.02 $0.03 - $0.06 31,416 4.06 $ 0.05 27,157 $ 0.05 $0.06 - $0.20 18,909 2.32 $ 0.07 18,909 $ 0.07 106,495 4.39 $ 0.04 69,757 $ 0.04
Summary of the status of the Company's non-vested shares	The following table summarizes the Company's non-vested option shares as of September 30, 2015: Non-vested Option Shares Shares Weighted Average Non-vested at January 1, 2015 14,954 $ 0.04 Granted 36,633 $ 0.02 Forfeited (1,020) $ 0.02 Vested (13,829) $ 0.03 Non-vested at September 30, 2015 36,738 $ 0.02
Information with respect to the classes of Preferred Stock	Preferred Stock Information with respect to the class of Preferred Stock at September 30, 2015 is as follows: Class of Annual Annual Liquidation Conversion Total Common Series A-1 8% Quarterly in $ 1.00 $ 0.1400 929 6,633 Series B 10% Quarterly in $ 1.50 $ 0.0433 13,191 304,430 Series C 10% Quarterly in $ 1.50 $ 0.0225 5,356 238,056 Series D-1 10% Quarterly in $ 1.00 $ 0.0225 7,878 350,127 Series D-2 10% Quarterly in $ 1.00 $ 0.0500 6,223 124,470
Information with respect to dividends issued on the Company's preferred stock	Information with respect to in-kind dividends issued on the Company's Preferred Stock for the three and nine-month periods ended September 30, 2015 and September 30, 2014 is as follows: Dividends Beneficial Conversion Feature Related to Dividends Three Months Ended Nine Months Ended Three Months Ended Nine Months Ended 2015 2014 2015 2014 2015 2014 2015 2014 Series A-1 $ 18 $ 22 $ 53 $ 63 $ - $ - $ - $ - Series B 324 294 939 852 - - - - Series C 132 119 382 345 - 64 13 114 Series D-1 192 128 516 329 - 107 16 151 Series D-2 153 145 445 400 - - - - Total $ 819 $ 708 $ 2,335 $ 1,989 $ - $ 171 $ 29 $ 265
Summary of the warrants issued	A summary of the warrant activity is as follows: September 30, 2015 September 30, 2014 Warrants Weighted Warrants Weighted Outstanding at beginning of period 213,521 $ 0.0289 77,155 $ 0.0289 Issued 40,560 0.0193 124,711 0.0275 Expired/Cancelled (16,259) 0.0500 (28,052) 0.0225 Outstanding at end of period 237,822 $ 0.0264 173,814 $ 0.0286 Exercisable at end of period 237,822 $ 0.0264 173,814 $ 0.0286
Status of the warrants outstanding	A summary of the status of the warrants outstanding and exercisable as of September 30, 2015 is as follows: Number of Warrants Weighted Average Remaining Life Weighted Average Exercise Price Warrants 27,400 2.52 $ 0.0225 Warrants 193,968 1.26 $ 0.0275 Warrants 3,294 0.13 $ 0.0500 Warrants 13,160 2.83 $ 0.0125 237,822 1.48 $ 0.0264

Nature of business, basis of 18

Nature of business, basis of presentation and summary of significant accounting policies (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and Cash Equivalents, at Carrying Value	$ 358	$ 775	$ 641	$ 945
Accumulated deficit	$ (126,082)	$ (123,199)

Concentrations (Details)

Concentrations (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			62.00%	77.00%
Accounts Receivable [Member] | Customer One [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			38.00%	46.00%
Accounts Receivable [Member] | Customer Two [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			24.00%
Accounts Receivable [Member] | Customer Four [Member]
Concentration Risk [Line Items]
Concentration risk, percentage				12.00%
Accounts Receivable [Member] | Customer Five [Member]
Concentration Risk [Line Items]
Concentration risk, percentage				19.00%
Sales Revenue, Services, Net [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	27.00%	39.00%	45.00%	35.00%
Sales Revenue, Services, Net [Member] | Customer One [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		17.00%	12.00%	11.00%
Sales Revenue, Services, Net [Member] | Customer Two [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	17.00%
Sales Revenue, Services, Net [Member] | Customer Three [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	10.00%	12.00%		10.00%
Sales Revenue, Services, Net [Member] | Customer Six [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		10.00%	16.00%
Sales Revenue, Services, Net [Member] | Customer Seven [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			17.00%	14.00%

Patents (Details)

Patents (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Amortizable intangible assets
Finite-lived intangible assets, gross	$ 6,745	$ 6,745
Finite-Lived intangible assets, accumulated amortization	(6,072)	(5,812)
Finite-lived intangible assets, net	$ 673	$ 933

Patents (Details Textual)

Patents (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Patent amortization expense	$ 87	$ 90	$ 260	$ 270
Patents impairment	$ 0	$ 0	$ 0	$ 0

Short-term note payable (Detail

Short-term note payable (Details Textual) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Debt Disclosure [Abstract]
Aggregate amount of demand note	$ 250
Stated percentage of demand short-term note	10.00%
Issuance Date of demand short-term note	Sep. 29, 2015

Net loss per share (Details)

Net loss per share (Details) - shares shares in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Series A Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	6,633	7,818
Series B Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	304,430	275,888
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	238,056	215,668
Series D One Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	350,127	251,435
Series D Two Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	124,470	112,737
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	106,495	70,960
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	237,822	173,814

Equity (Details)

Equity (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]
Risk-free interest rate, minimum	0.04%	0.04%
Risk-free interest rate, maximum	3.28%	3.73%
Expected volatility, minimum	120.74%	93.63%
Expected volatility, maximum	198.38%	198.38%
Expected dividend yield	$ 0	$ 0
Minimum [Member]
Fair value assumptions, stock options
Expected life	3 years 3 months 3 days	2 years 9 months 25 days
Maximum [Member]
Fair value assumptions, stock options
Expected life	6 years 3 months 29 days	7 years

Equity (Details 1)

Equity (Details 1) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 116	$ 65	$ 487	$ 342
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	35	16	148	64
Selling and Marketing Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	26	17	112	54
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	47	29	192	112
Director Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 8	$ 3	$ 35	$ 12

Equity (Details 2)

Equity (Details 2) - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Summary of stock options outstanding
Stock Options Outstanding, Beginning Balance			72,012	69,537
Stock Options, Granted			36,633	2,500
Stock Options, Exercised
Stock Options, Forfeited, or expired			(2,150)	(1,077)
Stock Options Outstanding, Ending Balance	106,495	70,960	106,495	70,960
Stock Options, Vested and expected to vest at ending balance	103,820	63,996	103,820	63,996
Options exercisable	69,757	55,102	69,757	55,102
Weighted Average Exercise Price, Beginning Period			$ 0.04	$ 0.05
Weighted Average Exercise Price, Granted			$ 0.02	$ 0.03
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited, or expired			$ 0.03	$ 0.05
Weighted Average Exercise Price, Ending Period	$ 0.04	$ 0.05	0.04	0.05
Weighted Average Exercise Price, Vested and expected to vest at ending balance	0.03	0.05	0.03	0.05
Weighted Average Exercise Price, Exercisable at ending balance	$ 0.04	$ 0.05	$ 0.04	$ 0.05
Weighted Average Remaining Contractual Term, ending balance			4 years 4 months 12 days	4 years 3 months 18 days
Weighted Average Remaining Contractual Term, vested and expected to vest at ending balance			3 years 2 months 15 days	4 years 3 months 18 days
Weighted Average Remaining Contractual Term, excercisable at ending balance			3 years 6 months 10 days	4 years 11 months 22 days
Aggregate Intrinsic Value, Beginning Balance
Aggregate Intrinsic Value, Granted
Aggregate Intrinsic Value, Exercised
Aggregate Intrinsic Value, Forfeited or expired
Aggregate Intrinsic Value, Ending Balance
Aggregate Intrinsic Value, Vested and expected to vest at ending balance
Aggregate Intrinsic Value, Exercisable at ending balance

Equity (Details 3)

Equity (Details 3) - $ / shares shares in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]
Number of Outstanding Options	106,495
Outstanding Options, Weighted Average Remaining Contractual Term	4 years 4 months 20 days
Outstanding Options, Weighted Average Exercise Price	$ 0.0224	$ 0.0273
Exercise Price Range, Number of Exercisable Options	69,757
Exercisable Options, Weighted Average Exercise Price	$ 0.04
Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, Lower Range Limit	0.01
Exercise Price Range, Upper Range Limit	$ 0.02
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]
Number of Outstanding Options	3,000
Outstanding Options, Weighted Average Remaining Contractual Term	6 years 2 months 22 days
Outstanding Options, Weighted Average Exercise Price	$ 0.02
Exercise Price Range, Number of Exercisable Options	584
Exercisable Options, Weighted Average Exercise Price	$ 0.02
Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, Lower Range Limit	0.02
Exercise Price Range, Upper Range Limit	$ 0.03
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]
Number of Outstanding Options	53,170
Outstanding Options, Weighted Average Remaining Contractual Term	5 years 2 months 15 days
Outstanding Options, Weighted Average Exercise Price	$ 0.02
Exercise Price Range, Number of Exercisable Options	23,107
Exercisable Options, Weighted Average Exercise Price	$ 0.02
Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, Lower Range Limit	0.03
Exercise Price Range, Upper Range Limit	$ 0.06
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]
Number of Outstanding Options	31,416
Outstanding Options, Weighted Average Remaining Contractual Term	4 years 21 days
Outstanding Options, Weighted Average Exercise Price	$ 0.05
Exercise Price Range, Number of Exercisable Options	27,157
Exercisable Options, Weighted Average Exercise Price	$ 0.05
Range Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, Lower Range Limit	0.06
Exercise Price Range, Upper Range Limit	$ 0.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]
Number of Outstanding Options	18,909
Outstanding Options, Weighted Average Remaining Contractual Term	2 years 3 months 25 days
Outstanding Options, Weighted Average Exercise Price	$ 0.07
Exercise Price Range, Number of Exercisable Options	18,909
Exercisable Options, Weighted Average Exercise Price	$ 0.07

Equity (Details 4)

Equity (Details 4) shares in Thousands	9 Months Ended
	Sep. 30, 2015$ / sharesshares
Equity Instruments, Options, Nonvested Shares Roll-Forward
Non-vested shares, Beginning Balance | shares	14,954
Non-vested shares, Granted | shares	36,633
Non-vested shares, Forfeited, or expired | shares	(1,020)
Non-vested shares, vested | shares	(13,829)
Stock Options Outstanding, Ending Balance | shares	36,738
Weighted Average Grant Date Fair Value, Options Nonvested at beginning of period	$ 0.04
Weighted Average Grant Date Fair Value, Options nonvested, grants in period	0.02
Weighted Average Grant Date Fair Value, Options nonvested, forfeited in period	0.02
Weighted Average Grant Date Fair Value, Options nonvested, vested in period	0.03
Weighted Average Grant Date Fair Value, Options nonvested at end of period	$ 0.02

Equity (Details 5)

Equity (Details 5)	3 Months Ended	9 Months Ended
	Sep. 30, 2015USD ($)$ / sharesshares	Sep. 30, 2015USD ($)$ / sharesshares
Annual Dividend	0.00%
Series A Preferred Stock [Member]
Annual Dividend		8.00%
Annual Dividend Payable, in Cash or In Kind		Quarterly in Arrears
Per Share Liquidation preference | $	$ 1	$ 1
Conversion price | $ / shares	$ 0.1400	$ 0.1400
Total Preferred Shares Outstanding	929,000	929,000
Common Shares to be Issued if Fully Converted	6,633,000	6,633,000
Series B Preferred Stock [Member]
Annual Dividend		10.00%
Annual Dividend Payable, in Cash or In Kind		Quarterly in Arrears
Per Share Liquidation preference | $	$ 1.50	$ 1.50
Conversion price | $ / shares	$ 0.0433	$ 0.0433
Total Preferred Shares Outstanding	13,191,000	13,191,000
Common Shares to be Issued if Fully Converted	304,430,000	304,430,000
Series C Preferred Stock [Member]
Annual Dividend		10.00%
Annual Dividend Payable, in Cash or In Kind		Quarterly in Arrears
Per Share Liquidation preference | $	$ 1.50	$ 1.50
Conversion price | $ / shares	$ 0.0225	$ 0.0225
Total Preferred Shares Outstanding	5,356,000	5,356,000
Common Shares to be Issued if Fully Converted	238,056,000	238,056,000
Series D One Preferred Stock [Member]
Annual Dividend		10.00%
Annual Dividend Payable, in Cash or In Kind		Quarterly in Arrears
Per Share Liquidation preference | $	$ 1	$ 1
Conversion price | $ / shares	$ 0.0225	$ 0.0225
Total Preferred Shares Outstanding	7,878,000	7,878,000
Common Shares to be Issued if Fully Converted	350,127,000	350,127,000
Series D Two Preferred Stock [Member]
Annual Dividend		10.00%
Annual Dividend Payable, in Cash or In Kind		Quarterly in Arrears
Per Share Liquidation preference | $	$ 1	$ 1
Conversion price | $ / shares	$ 0.0500	$ 0.0500
Total Preferred Shares Outstanding	6,223,000	6,223,000
Common Shares to be Issued if Fully Converted	124,470,000	124,470,000

Equity (Details 6)

Equity (Details 6) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
YTD Dividend Shares in Kind	$ 819	$ 708	$ 2,335	$ 1,989
Accretion of beneficial conversion feature related to dividends		171	29	265
Series A Preferred Stock [Member]
YTD Dividend Shares in Kind	$ 18	$ 22	$ 53	$ 63
Accretion of beneficial conversion feature related to dividends
Series B Preferred Stock [Member]
YTD Dividend Shares in Kind	$ 324	$ 294	$ 939	$ 852
Accretion of beneficial conversion feature related to dividends
Series C Preferred Stock [Member]
YTD Dividend Shares in Kind	$ 132	$ 119	$ 382	$ 345
Accretion of beneficial conversion feature related to dividends		64	13	114
Series D One Preferred Stock [Member]
YTD Dividend Shares in Kind	$ 192	128	516	329
Accretion of beneficial conversion feature related to dividends		107	16	151
Series D Two Preferred Stock [Member]
YTD Dividend Shares in Kind	$ 153	$ 145	$ 445	$ 400
Accretion of beneficial conversion feature related to dividends

Equity (Details 7)

Equity (Details 7) shares in Thousands	9 Months Ended
	Sep. 30, 2015$ / sharesshares	Sep. 30, 2014$ / sharesshares
Class Of Warrant Or Right Number Of Warrants Or Rights Roll Forward
Number of Warrants Outstanding at beginning of period | shares	213,521	77,155
Number of warrants issued | shares	40,560	124,711
Number Of Warrants Or Rights Exercised | shares
Number Of Warrants Or Rights Expired | shares	(16,259)	(28,052)
Number of Warrants Outstanding at end of period | shares	237,822	173,814
Number of Warrants Or Rights Exercisable at end of period | shares	237,822	173,814
Excercise Price of Warrants Outstanding at beginning of period	$ 0.0289	$ 0.0289
Exercise Price Of Warrants Issued	0.0193	0.0275
Exercise Price Of Warrants Exercised
Exercise Price Of Warrants Expired	0.0500	0.0225
Excercise Price of Warrants Outstanding at end of period	$ 0.0264	$ 0.0286
Exercise Price Of WarrantsExercisable at end of period	0.0264	0.0286

Equity (Details 8)

Equity (Details 8) - $ / shares shares in Thousands	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Number of Warrants Outstanding and Excercisable	237,822	213,521	173,814	77,155
Weighted Average Remaining Life Of Warrants Or Rights	1 year 5 months 22 days
Warrants Weighted Average Exercise Price	$ 0.0264	$ 0.0289	$ 0.0286	$ 0.0289
Warrants Group One [Member]
Class of Warrant or Right [Line Items]
Number of Warrants Outstanding and Excercisable	27,400
Weighted Average Remaining Life Of Warrants Or Rights	2 years 6 months 6 days
Warrants Weighted Average Exercise Price	$ 0.0225
Warrants Group Two [Member]
Class of Warrant or Right [Line Items]
Number of Warrants Outstanding and Excercisable	193,968
Weighted Average Remaining Life Of Warrants Or Rights	1 year 3 months 3 days
Warrants Weighted Average Exercise Price	$ 0.0275
Warrants Group Three [Member]
Class of Warrant or Right [Line Items]
Number of Warrants Outstanding and Excercisable	3,294
Weighted Average Remaining Life Of Warrants Or Rights	1 month 16 days
Warrants Weighted Average Exercise Price	$ 0.0500
Warrants Group Four [Member]
Class of Warrant or Right [Line Items]
Number of Warrants Outstanding and Excercisable	13,160
Weighted Average Remaining Life Of Warrants Or Rights	2 years 9 months 28 days
Warrants Weighted Average Exercise Price	$ 0.0125

Equity (Details Textual)

Equity (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share-based Arrangements with Employees and Nonemployees [Abstract]
Estimated average forfeiture rate	7.89%	9.75%
Stock Options, Granted			36,633	2,500
Outstanding Options, Weighted Average Exercise Price	$ 0.0224	$ 0.0273	$ 0.0224	$ 0.0273
Stock Options, Exercised
Total unrecognized compensation expense related to non-vested share-based compensation arrangements granted under the plans	$ 363		$ 363
Unrecognized compensation expense amortization period	3 years 2 months 12 days

Equity (Details Textual 1)

Equity (Details Textual 1) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	1 Months Ended
	Jul. 31, 2015	Mar. 31, 2015	Feb. 28, 2015	Mar. 31, 2014	Feb. 28, 2014	Sep. 30, 2015	Jul. 23, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
Subsidiary, Sale of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.0264		$ 0.0289	$ 0.0286	$ 0.0289
Venture Champion Asia Limited [Member]
Subsidiary, Sale of Stock [Line Items]
Credit Agreement origination date			May 6, 2014
Line of Credit Facility, Current Borrowing Capacity			$ 2,000
Line of Credit Facility, Fair Value of Amount Outstanding			$ 0
Credit Agreement expiration date			Feb. 23, 2015
Warrants Issued to SG Phoenix [Member]
Subsidiary, Sale of Stock [Line Items]
Fair Value Assumptions, Expected Term				3 years
Number of common shares callable by warrants				3,000
Warrants Issued to Unrelated Parties [Member]
Subsidiary, Sale of Stock [Line Items]
Fair Value Assumptions, Expected Term				3 years
Number of common shares callable by warrants				1,600
Series D Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Proceeds from sale of stock, net	$ 325	$ 1,200		$ 406	$ 733
Administrative fee	$ 4	$ 33		$ 4	$ 47
Warrant coverage, maximum percentage				100.00%	100.00%
Fair Value Assumptions, Expected Term		3 years
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.0025					$ 0.0125
Warrants, expiration date	Jul. 22, 2018	Mar. 31, 2018		Dec. 31, 2016	Dec. 31, 2016
Number of common shares callable by warrants		27,400					13,160
Warrants And Rights Issued Fair Value Initial		$ 366					$ 91
Series D One Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares sold in private placement	329	1,233		273	520
Series D Two Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares sold in private placement				137	260
Note Warrant [Member] | Venture Champion Asia Limited [Member]
Subsidiary, Sale of Stock [Line Items]
Number of common shares callable by warrants			10,909